IL191317A - Use of cells for the preparation of a pharmaceutical preparation for complementary treatment - Google Patents

Use of cells for the preparation of a pharmaceutical preparation for complementary treatment

Info

Publication number
IL191317A
IL191317A IL191317A IL19131708A IL191317A IL 191317 A IL191317 A IL 191317A IL 191317 A IL191317 A IL 191317A IL 19131708 A IL19131708 A IL 19131708A IL 191317 A IL191317 A IL 191317A
Authority
IL
Israel
Prior art keywords
cells
manufacture
pharmaceutical composition
adjunctive treatment
adjunctive
Prior art date
Application number
IL191317A
Other languages
English (en)
Hebrew (he)
Other versions
IL191317A0 (en
Original Assignee
Univ Oregon Health & Science
Abt Holding Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Oregon Health & Science, Abt Holding Co filed Critical Univ Oregon Health & Science
Publication of IL191317A0 publication Critical patent/IL191317A0/en
Publication of IL191317A publication Critical patent/IL191317A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61N—ELECTROTHERAPY; MAGNETOTHERAPY; RADIATION THERAPY; ULTRASOUND THERAPY
    • A61N5/00—Radiation therapy
    • A61N5/10—X-ray therapy; Gamma-ray therapy; Particle-irradiation therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0607—Non-embryonic pluripotent stem cells, e.g. MASC
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Oncology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Materials For Medical Uses (AREA)
IL191317A 2005-11-09 2008-05-07 Use of cells for the preparation of a pharmaceutical preparation for complementary treatment IL191317A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11/269,736 US8147824B2 (en) 1999-08-05 2005-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
PCT/US2006/043804 WO2007056578A1 (en) 2005-11-09 2006-11-09 Immunomodulatory properties of multipotent adult progenitor cells and uses thereof

Publications (2)

Publication Number Publication Date
IL191317A0 IL191317A0 (en) 2008-12-29
IL191317A true IL191317A (en) 2015-03-31

Family

ID=37808258

Family Applications (5)

Application Number Title Priority Date Filing Date
IL191317A IL191317A (en) 2005-11-09 2008-05-07 Use of cells for the preparation of a pharmaceutical preparation for complementary treatment
IL236832A IL236832A (en) 2005-11-09 2015-01-21 Use of cells for the preparation of adjuvant for adjuvant therapy
IL249572A IL249572B (en) 2005-11-09 2016-12-14 Immunological properties of multipotent cells and their use
IL276705A IL276705B (en) 2005-11-09 2020-08-13 Immunological properties of multipotent cells and their use
IL289024A IL289024A (en) 2005-11-09 2021-12-15 Immunological properties of multipotent cells and their use

Family Applications After (4)

Application Number Title Priority Date Filing Date
IL236832A IL236832A (en) 2005-11-09 2015-01-21 Use of cells for the preparation of adjuvant for adjuvant therapy
IL249572A IL249572B (en) 2005-11-09 2016-12-14 Immunological properties of multipotent cells and their use
IL276705A IL276705B (en) 2005-11-09 2020-08-13 Immunological properties of multipotent cells and their use
IL289024A IL289024A (en) 2005-11-09 2021-12-15 Immunological properties of multipotent cells and their use

Country Status (19)

Country Link
US (6) US8147824B2 (cg-RX-API-DMAC7.html)
EP (3) EP1951294B1 (cg-RX-API-DMAC7.html)
JP (3) JP5399709B2 (cg-RX-API-DMAC7.html)
KR (1) KR101423786B1 (cg-RX-API-DMAC7.html)
CN (3) CN101336112B (cg-RX-API-DMAC7.html)
AU (1) AU2006311418B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0618486B1 (cg-RX-API-DMAC7.html)
CA (3) CA3206592A1 (cg-RX-API-DMAC7.html)
DK (2) DK1951294T3 (cg-RX-API-DMAC7.html)
ES (2) ES2778424T3 (cg-RX-API-DMAC7.html)
HU (1) HUE055956T2 (cg-RX-API-DMAC7.html)
IL (5) IL191317A (cg-RX-API-DMAC7.html)
LT (1) LT1951294T (cg-RX-API-DMAC7.html)
NZ (2) NZ596022A (cg-RX-API-DMAC7.html)
PH (2) PH12021551194A1 (cg-RX-API-DMAC7.html)
PL (2) PL1951294T3 (cg-RX-API-DMAC7.html)
PT (2) PT2684571T (cg-RX-API-DMAC7.html)
RU (1) RU2497530C2 (cg-RX-API-DMAC7.html)
WO (1) WO2007056578A1 (cg-RX-API-DMAC7.html)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10638734B2 (en) 2004-01-05 2020-05-05 Abt Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US8252280B1 (en) 1999-08-05 2012-08-28 Regents Of The University Of Minnesota MAPC generation of muscle
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US7311905B2 (en) 2002-02-13 2007-12-25 Anthrogenesis Corporation Embryonic-like stem cells derived from post-partum mammalian placenta, and uses and methods of treatment using said cells
KR100915482B1 (ko) 2000-12-06 2009-09-03 하리리 로버트 제이 태반 줄기 세포의 회수 방법
ES2548591T3 (es) 2001-02-14 2015-10-19 Anthrogenesis Corporation Placenta post-parto de mamífero, su uso y células madre placentarias de la misma
EP2336299A1 (en) * 2001-02-14 2011-06-22 Anthrogenesis Corporation Post-partum mammalian placenta, its use and placental stem cells therefrom
EP1491093B1 (en) * 2001-02-14 2013-07-31 ABT Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
DE10144326B4 (de) * 2001-09-10 2005-09-22 Siemens Ag Verfahren und System zur Überwachung eines Reifenluftdrucks
US8192348B2 (en) * 2003-07-01 2012-06-05 Regents Of The University Of Minnesota Engineered blood vessels
MX343814B (es) 2005-10-13 2016-11-24 Anthrogenesis Corp Inmunomodulación usando celulas madre de la placenta.
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
EP2471903B1 (en) 2005-12-29 2018-02-14 Anthrogenesis Corporation Placental stem cell populations
EP1976978A2 (en) 2005-12-29 2008-10-08 Anthrogenesis Corporation Co-culture of placental stem cells and stem cells from a second source
EP1971679B1 (en) 2006-01-13 2013-04-10 Osiris Therapeutics, Inc. Mesenchymal stem cells expressing tnf- receptor
NZ727755A (en) 2006-01-23 2023-01-27 Abt Holding Co Mapc therapeutics without adjunctive immunosuppressive treatment
US20110171182A1 (en) * 2006-03-23 2011-07-14 Pluristem Ltd. Methods for cell expansion and uses of cells and conditioned media produced thereby for therapy
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
EP2418271A3 (en) 2006-10-23 2015-09-30 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
AU2007321928A1 (en) * 2006-11-24 2008-05-29 Regents Of The University Of Minnesota Endodermal progenitor cells
CN101657206B (zh) 2007-02-12 2013-07-03 人类起源公司 利用胎盘干细胞治疗炎性疾病
CN101878034B (zh) 2007-09-28 2013-11-20 细胞基因细胞疗法公司 使用人胎盘灌洗液和人来自胎盘的中间体自然杀伤细胞的肿瘤抑制
AU2008331501B2 (en) * 2007-11-30 2014-09-04 New York Medical College Methods of isolating non-senescent cardiac stem cells and uses thereof
US20090162329A1 (en) * 2007-11-30 2009-06-25 Piero Anversa Compositions comprising hdac inhibitors and methods of their use in restoring stem cell function and preventing heart failure
CA2743698A1 (en) * 2007-11-30 2009-06-11 New York Medical College Compositions comprising vascular and myocyte progenitor cells and methods of their use
CA2743682A1 (en) 2007-11-30 2009-06-11 New York Medical College Methods of reducing transplant rejection and cardiac allograft vasculopathy by implanting autologous stem cells
US8512696B2 (en) * 2007-11-30 2013-08-20 Autologous, Llc Methods of isolating non-senescent cardiac stem cells and uses thereof
WO2009092092A1 (en) 2008-01-18 2009-07-23 Regents Of The University Of Minnesota Stem cell aggregates and methods for making and using
KR20240052847A (ko) 2008-08-20 2024-04-23 셀룰래리티 인코포레이티드 개선된 세포 조성물 및 그의 제조 방법
JP5950577B2 (ja) 2008-08-20 2016-07-13 アンスロジェネシス コーポレーション 単離胎盤細胞を使用した脳卒中の治療
US8728805B2 (en) 2008-08-22 2014-05-20 Anthrogenesis Corporation Methods and compositions for treatment of bone defects with placental cell populations
NZ592726A (en) 2008-11-19 2012-12-21 Anthrogenesis Corp Amnion derived adherent cells
US20110020292A1 (en) * 2009-07-21 2011-01-27 Abt Holding Company Use of Stem Cells to Reduce Leukocyte Extravasation
EP3831930A1 (en) * 2009-07-21 2021-06-09 ABT Holding Company Use of stem cells to reduce leukocyte extravasation
ES2646750T3 (es) 2010-01-26 2017-12-15 Anthrogenesis Corporation Tratamiento de cánceres relacionados con hueso utilizando células madre placentarias
LT2556145T (lt) 2010-04-07 2016-11-10 Anthrogenesis Corporation Angiogenezė naudojant placentos kamienines ląsteles
MX2012011543A (es) 2010-04-08 2013-05-06 Anthrogenesis Corp Tratamiento de sarcoidosis empleando celulas madre placentarias.
CA2798895A1 (en) 2010-05-12 2011-11-17 Abt Holding Company Modulation of splenocytes in cell therapy
JP5996533B2 (ja) 2010-07-13 2016-09-21 アントフロゲネシス コーポレーション ナチュラルキラー細胞を生成させる方法
US8642027B2 (en) 2010-09-01 2014-02-04 Stemnion, Inc. Compositions and methods for modulating ischemic injury
US8895291B2 (en) 2010-10-08 2014-11-25 Terumo Bct, Inc. Methods and systems of growing and harvesting cells in a hollow fiber bioreactor system with control conditions
US20120087933A1 (en) 2010-10-08 2012-04-12 Samson Tom Enhanced msc preparations
US8969315B2 (en) 2010-12-31 2015-03-03 Anthrogenesis Corporation Enhancement of placental stem cell potency using modulatory RNA molecules
EP2714059B1 (en) 2011-06-01 2018-10-03 Celularity, Inc. Treatment of pain using placental stem cells
DK2718416T3 (da) * 2011-06-06 2020-02-24 ReGenesys BVBA Ekspansion af stamceller i hulfiberbioreaktorer
US9925221B2 (en) 2011-09-09 2018-03-27 Celularity, Inc. Treatment of amyotrophic lateral sclerosis using placental stem cells
AU2012346645B2 (en) * 2011-12-01 2015-08-27 R Bio Co., Ltd. Culture-medium composition for rejuvenating stem cells
CA3210893A1 (en) 2012-01-13 2013-07-18 The General Hospital Corporation Isolated human lung progenitor cells and uses thereof
WO2014015318A1 (en) * 2012-07-19 2014-01-23 Bluebird Bio, Inc. Soluble compounds for improved gene therapy methods
US9763983B2 (en) 2013-02-05 2017-09-19 Anthrogenesis Corporation Natural killer cells from placenta
WO2014125277A1 (en) 2013-02-12 2014-08-21 Reneuron Limited Method of producing microparticles
IL289870B2 (en) * 2013-04-12 2023-03-01 Lafrancesca Saverio Improving organs for transplantation
DK2992088T3 (da) * 2013-04-30 2019-11-11 Univ Leuven Kath Celleterapi for myelodysplastiske syndromer
JP6633522B2 (ja) 2013-11-16 2020-01-22 テルモ ビーシーティー、インコーポレーテッド バイオリアクターにおける細胞増殖
ITFI20130303A1 (it) * 2013-12-24 2015-06-25 Azienda Ospedaliero Universitaria M Eyer Metodica per l¿isolamento, purificazione ed amplificazione di progenitori renali cd133+cd24+ dalle urine di pazienti affetti da malattie renali.
CN106232800B (zh) 2014-03-25 2020-07-03 泰尔茂比司特公司 介质的被动替代
JP6830059B2 (ja) 2014-09-26 2021-02-17 テルモ ビーシーティー、インコーポレーテッド スケジュール化された細胞フィーディング
RU2580640C1 (ru) * 2014-12-25 2016-04-10 Федеральное государственное бюджетное учреждение "Федеральный научный центр трансплантологии и искусственных органов имени академика В.И. Шумакова" Министерства здравоохранения Российской Федерации Способ профилактики гуморального отторжения при аво-несовместимой трансплантации печени детям раннего возраста
WO2017004592A1 (en) 2015-07-02 2017-01-05 Terumo Bct, Inc. Cell growth with mechanical stimuli
KR20180102661A (ko) 2016-01-21 2018-09-17 에이비티 홀딩 컴퍼니 상처 치유를 위한 줄기 세포
EP3464565A4 (en) 2016-05-25 2020-01-01 Terumo BCT, Inc. CELL EXPANSION
US11685883B2 (en) 2016-06-07 2023-06-27 Terumo Bct, Inc. Methods and systems for coating a cell growth surface
US11104874B2 (en) 2016-06-07 2021-08-31 Terumo Bct, Inc. Coating a bioreactor
US10767164B2 (en) 2017-03-30 2020-09-08 The Research Foundation For The State University Of New York Microenvironments for self-assembly of islet organoids from stem cells differentiation
US12234441B2 (en) 2017-03-31 2025-02-25 Terumo Bct, Inc. Cell expansion
US11624046B2 (en) 2017-03-31 2023-04-11 Terumo Bct, Inc. Cell expansion
EP3656842A1 (en) 2017-03-31 2020-05-27 Terumo BCT, Inc. Cell expansion
WO2018186421A1 (ja) 2017-04-03 2018-10-11 株式会社カネカ 間葉系幹細胞を含む細胞集団とその製造方法、及び医薬組成物
CN107714726A (zh) * 2017-10-16 2018-02-23 中国科学院广州生物医药与健康研究院 一种重塑骨髓微环境的方法
WO2019102268A1 (en) 2017-11-22 2019-05-31 Mesoblast International Sarl Cellular compositions and methods of treatment i
CN111566205B (zh) 2017-12-28 2024-10-29 株式会社钟化 包含贴壁性干细胞的细胞群、其制备方法、以及医药组合物
EP3750987A4 (en) 2017-12-28 2021-11-10 Kaneka Corporation CELL POPULATION INCLUDING ADHESIVE STEM CELLS, ITS PRODUCTION PROCESS, AND PHARMACEUTICAL COMPOSITION
CN109735611A (zh) * 2018-12-19 2019-05-10 珠海铂华生物工程有限公司 一种用于检测骨髓衰竭综合征的基因组合、引物库、构建高通量测序文库的方法及其应用
JPWO2020184350A1 (cg-RX-API-DMAC7.html) 2019-03-08 2020-09-17
JP7705950B2 (ja) 2021-03-23 2025-07-10 テルモ ビーシーティー、インコーポレーテッド 細胞を増殖する方法
EP4426815A1 (en) 2021-11-05 2024-09-11 Healios K.K. Culture-expanded canine progenitor cells and related methods
US12152699B2 (en) 2022-02-28 2024-11-26 Terumo Bct, Inc. Multiple-tube pinch valve assembly
USD1099116S1 (en) 2022-09-01 2025-10-21 Terumo Bct, Inc. Display screen or portion thereof with a graphical user interface for displaying cell culture process steps and measurements of an associated bioreactor device
CN120129527A (zh) * 2022-09-02 2025-06-10 财团法人医药工业技术发展中心 包含间充质干细胞的组合物在缓解骨髓纤维化上的用途

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4353888A (en) 1980-12-23 1982-10-12 Sefton Michael V Encapsulation of live animal cells
US4749620A (en) 1984-02-15 1988-06-07 Massachusetts Institute Of Technology Encapsulated active material system
US4744933A (en) 1984-02-15 1988-05-17 Massachusetts Institute Of Technology Process for encapsulation and encapsulated active material system
JPH0628570B2 (ja) 1986-02-13 1994-04-20 雪印乳業株式会社 カプセル体の製造方法及び装置
EP0301777A1 (en) 1987-07-28 1989-02-01 Queen's University At Kingston Multiple membrane microencapsulation
US5089272A (en) 1989-03-29 1992-02-18 Snow Brand Milk Products Co., Ltd. Process for producing capsules having a permeability-controllable membrane
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
US5578442A (en) 1992-03-23 1996-11-26 Vivorx, Inc. Graft copolymers of polycationic species and water-soluble polymers, and use therefor
US6270766B1 (en) * 1992-10-08 2001-08-07 The Kennedy Institute Of Rheumatology Anti-TNF antibodies and methotrexate in the treatment of arthritis and crohn's disease
EP1179350A3 (en) 1993-08-12 2003-01-02 Cytotherapeutics, Inc. Encapsulated cell system for implantation into the human CNS
JPH07316051A (ja) 1994-05-23 1995-12-05 Kanegafuchi Chem Ind Co Ltd 免疫抑制剤としてのベルベリン
IN184685B (cg-RX-API-DMAC7.html) 1996-02-14 2000-09-23 Nat Inst Immunology
US6306434B1 (en) 1997-02-12 2001-10-23 Chong Kun Dang Corp. Pharmaceutical composition comprising cyclosporin solid-state microemulsion
US7514074B2 (en) 1997-07-14 2009-04-07 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
US20030103951A1 (en) 1997-07-14 2003-06-05 Osiris Therapeutics, Inc. Cardiac muscle regeneration using mesenchymal stem cells
ATE307195T1 (de) 1997-07-14 2005-11-15 Osiris Therapeutics Inc Herzmuskelregenerierung unter verwendung mesenchymaler stammzellen
AU749675B2 (en) 1998-03-13 2002-07-04 Mesoblast International Sarl Uses for human non-autologous mesenchymal stem cells
PT1066052E (pt) 1998-03-18 2006-06-30 Osiris Therapeutics Inc Celulas estaminais mesenquimatosas para a prevencao e tratamento
US6368636B1 (en) 1998-03-18 2002-04-09 Osiris Therapeutics, Inc. Mesenchymal stem cells for prevention and treatment of immune responses in transplantation
DK1066060T3 (da) 1998-04-03 2003-11-24 Osiris Therapeutics Inc Mesenkymale stamceller som immunsuppresive midler
EP1070135B1 (en) * 1998-04-08 2010-02-24 Metabolix, Inc. Methods for separation and purification of biopolymers
CA2244554A1 (en) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition of graft versus host disease
US6060364A (en) * 1999-03-02 2000-05-09 Advanced Micro Devices, Inc. Fast Mosfet with low-doped source/drain
US7015037B1 (en) 1999-08-05 2006-03-21 Regents Of The University Of Minnesota Multiponent adult stem cells and methods for isolation
US7927587B2 (en) 1999-08-05 2011-04-19 Regents Of The University Of Minnesota MAPC administration for the treatment of lysosomal storage disorders
US8147824B2 (en) 1999-08-05 2012-04-03 Athersys, Inc. Immunomodulatory properties of multipotent adult progenitor cells and uses thereof
US8075881B2 (en) 1999-08-05 2011-12-13 Regents Of The University Of Minnesota Use of multipotent adult stem cells in treatment of myocardial infarction and congestive heart failure
DK1226233T3 (da) * 1999-08-05 2011-10-03 Abt Holding Co Multipotente voksne stamceller og fremgangsmåder til isolering heraf
US6685936B2 (en) 1999-10-12 2004-02-03 Osiris Therapeutics, Inc. Suppressor cells induced by culture with mesenchymal stem cells for treatment of immune responses in transplantation
JP2004529614A (ja) 2000-11-20 2004-09-30 カリフォルニア・インスティテュート・オブ・テクノロジー 動脈平滑筋及び静脈平滑筋並びにそれらの利用
US20030044843A1 (en) 2001-01-09 2003-03-06 Mitsubishi Pharma Corporation Novel proteome analysis method and devices therefor
EP1491093B1 (en) * 2001-02-14 2013-07-31 ABT Holding Company Multipotent adult stem cells, sources thereof, methods of obtaining and maintaining same, methods of differentiation thereof, methods of use thereof and cells derived thereof
US9969980B2 (en) 2001-09-21 2018-05-15 Garnet Biotherapeutics Cell populations which co-express CD49c and CD90
AU2003202988A1 (en) 2002-01-14 2003-07-30 The Board Of Trustees Of The University Of Illinois Use of modified pyrimidine compounds to promote stem cell migration and proliferation
US20040037811A1 (en) 2002-08-22 2004-02-26 The Cleveland Clinic Foundation Stromal cell-derived factor-1 mediates stem cell homing and tissue regeneration in ischemic cardiomyopathy
US7105037B2 (en) 2002-10-31 2006-09-12 Advanced Technology Materials, Inc. Semiconductor manufacturing facility utilizing exhaust recirculation
US7807458B2 (en) 2003-01-30 2010-10-05 The United States Of America As Represented By The Secretary Of The Department Of Veterans Affairs Multilineage-inducible cells and uses thereof
WO2004099395A2 (en) 2003-05-08 2004-11-18 Cellartis Ab A method for the generation of neural progenitor cells
PL1641916T3 (pl) 2003-06-27 2016-08-31 Depuy Synthes Products Inc Regeneracja i naprawa tkanki nerwowej z wykorzystaniem komórek poporodowych
US8426200B2 (en) * 2003-07-02 2013-04-23 Regents Of The University Of Minnesota Neuronal differentiation of stem cells
EP1737947B9 (en) 2004-04-21 2012-04-25 Regents Of The University Of Minnesota Mapc generation of lung tissue
AU2005331534B2 (en) 2005-05-05 2011-12-08 Regents Of The University Of Minnesota Use of MAPC or progeny therefrom to populate lymphohematopoietic tissues
CN101218341A (zh) 2005-05-05 2008-07-09 明尼苏达大学董事会 Nk细胞抑制作用用于促进定植的mhc-i阴性细胞持续存在的用途
TW200726474A (en) 2005-07-15 2007-07-16 Cognate Therapeutics Inc The immunophenotype and immunogenicity of human adipose derived cells
JP5203212B2 (ja) 2005-10-13 2013-06-05 アントフロゲネシス コーポレーション 胎盤由来幹細胞からのオリゴデンドロサイトの産生
US11000546B2 (en) 2005-11-09 2021-05-11 Athersys, Inc. Immunomodulatory properties of MAPCs and uses thereof
US10117900B2 (en) 2005-11-09 2018-11-06 Athersys, Inc. MAPC treatment of brain injuries and diseases
NZ727755A (en) 2006-01-23 2023-01-27 Abt Holding Co Mapc therapeutics without adjunctive immunosuppressive treatment
US7993918B2 (en) 2006-08-04 2011-08-09 Anthrogenesis Corporation Tumor suppression using placental stem cells
CN101657206B (zh) 2007-02-12 2013-07-03 人类起源公司 利用胎盘干细胞治疗炎性疾病
US20120121545A1 (en) 2009-01-15 2012-05-17 Corestem Co., Ltd. Pharmaceutical Composition For Bone Disease Treatment Or Countering Inflammation, Comprising Cartilage Stem Cells As An Active Principle
EP2241617A1 (en) 2009-04-06 2010-10-20 Rijksuniversiteit Groningen Multipotent cells derived from blood and methods and uses related thereto

Also Published As

Publication number Publication date
US20090104163A1 (en) 2009-04-23
JP5399709B2 (ja) 2014-01-29
US20060263337A1 (en) 2006-11-23
NZ568546A (en) 2012-06-29
CN101336112B (zh) 2015-05-20
RU2497530C2 (ru) 2013-11-10
LT1951294T (lt) 2020-04-10
CN104873540B (zh) 2019-11-15
DK2684571T3 (da) 2021-08-30
EP3808373A1 (en) 2021-04-21
BRPI0618486A2 (pt) 2011-08-30
PT2684571T (pt) 2021-08-30
EP1951294B1 (en) 2019-12-25
IL289024A (en) 2022-02-01
IL249572B (en) 2020-08-31
IL236832A (en) 2017-08-31
CA2628254A1 (en) 2007-05-18
US20180055881A1 (en) 2018-03-01
CA2628254C (en) 2023-06-20
PT1951294T (pt) 2020-03-31
EP2684571A1 (en) 2014-01-15
PH12015502169A1 (en) 2017-04-24
US11197889B2 (en) 2021-12-14
CN101336112A (zh) 2008-12-31
PH12015502169B1 (en) 2022-02-11
CA3028315C (en) 2023-09-05
KR20080092336A (ko) 2008-10-15
PL2684571T3 (pl) 2022-01-10
CA3206592A1 (en) 2007-05-18
WO2007056578A1 (en) 2007-05-18
PL1951294T3 (pl) 2020-08-24
HUE055956T2 (hu) 2022-01-28
BRPI0618486B1 (pt) 2021-11-30
AU2006311418B2 (en) 2013-03-14
KR101423786B1 (ko) 2014-07-25
CN104095878A (zh) 2014-10-15
CA3028315A1 (en) 2007-05-18
US9962407B2 (en) 2018-05-08
JP5897514B2 (ja) 2016-03-30
JP2016135763A (ja) 2016-07-28
IL249572A0 (en) 2017-02-28
PH12021551194A1 (en) 2023-04-24
IL276705B (en) 2022-04-01
RU2008122943A (ru) 2009-12-20
CN104873540A (zh) 2015-09-02
AU2006311418A1 (en) 2007-05-18
ES2778424T3 (es) 2020-08-10
HK1203058A1 (en) 2015-10-16
EP1951294A1 (en) 2008-08-06
US20210346429A1 (en) 2021-11-11
JP2009514979A (ja) 2009-04-09
JP2013256510A (ja) 2013-12-26
US9808485B2 (en) 2017-11-07
HK1214166A1 (zh) 2016-07-22
EP2684571B1 (en) 2021-05-26
DK1951294T3 (da) 2020-03-23
US20120135043A1 (en) 2012-05-31
US20150118193A1 (en) 2015-04-30
CN104095878B (zh) 2020-01-21
IL276705A (en) 2020-09-30
JP6342880B2 (ja) 2018-06-13
IL191317A0 (en) 2008-12-29
ES2884703T3 (es) 2021-12-10
US8147824B2 (en) 2012-04-03
NZ596022A (en) 2013-06-28

Similar Documents

Publication Publication Date Title
IL191317A (en) Use of cells for the preparation of a pharmaceutical preparation for complementary treatment
IL185462A0 (en) New pharmaceutical compositions useful in the treatment of pain
IL183101A (en) Use of tetrahydrocannabivarin in drug production
SI3424932T1 (sl) Boronoftalidi za terapevtsko uporabo
IL191356A0 (en) Therapeutic materials
PT1978947E (pt) Derivados nitro-óxido para utilização no tratamento de distrofias musculares
ZA200802272B (en) Novel dosage formulation
GB0400700D0 (en) Compounds useful in therapy
EP1757282A4 (en) USE OF KAURANE COMPOUNDS IN THE MANUFACTURE OF MEDICAMENTS
EP1834624A4 (en) MEDICAL COMPOSITION AND MANUFACTURING METHOD THEREFOR
IL186851A0 (en) Styrylsulfonamides, their manufacture and use as pharmaceutical agents
ZA200700844B (en) Quinolone-containing medicinal composition
GB0410582D0 (en) Compositions for use in the manufacture of lenses
GB0501655D0 (en) Therapeutic use
SI1714647T1 (sl) Uporaba agomelatina pri izdelavi zdravila za zdravljenje bipolarnih motenj
GB0526292D0 (en) A composition for use in the treatment of a surface
PL1688129T3 (pl) Nowy preparat terapeutyczny
GB0517043D0 (en) Improvements in pharmaceutical compositions
GB0516610D0 (en) Compounds for use in therapy
EP1956001A4 (en) PHARMACEUTICAL PRODUCT FOR USE IN THE TREATMENT OF URETEROLITHIASE
GB0402799D0 (en) Pharmaceutical composition
GB0510814D0 (en) Compounds for use in therapy
GB0515900D0 (en) Compounds for use in therapy
GB0510815D0 (en) Compounds for use in therapy
HK1110217A (en) New pharmaceutical compositions useful in the treatment of pain

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed
KB Patent renewed